Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:24 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 10,858 matching trials from the live ClinicalTrials.gov search.
Filters: Nashville, Tennessee Clear all
Recruiting Phase 3 Interventional

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
42
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional

Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers

NCT00389792
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
ATI-2042, ATI-2042 200 mg
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Nov 3, 2026, 5:24 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Not applicable Interventional Results available

Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter

NCT02649894
View directory record Official record
Conditions
Malignant Pleural Effusion
Interventions
Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter, Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Huntsville, Alabama • Stanford, California • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 3, 2026, 5:24 AM EST
Active, not recruiting Phase 1 Interventional

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
JNJ-80948543
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Duarte, California • New York, New York • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed No phase listed Observational

Data Collection Study of Wedge Pressure Data in Patients With CRT-D Devices

NCT00811551
View directory record Official record
Conditions
Heart Failure
Interventions
CRT-D (Intra-thoracic Impedance Monitoring)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Little Rock, Arkansas • Pasadena, California • Colorado Springs, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Nov 3, 2026, 5:24 AM EST
Terminated Phase 3 Interventional Results available

Minimize Menorrhagia in Women With Von Willebrand Disease

NCT02606045
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
recombinant von Willebrand factor, tranexamic acid
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional Results available

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

NCT05014672
View directory record Official record
Conditions
Primary Biliary Cholangitis, Liver Stiffness
Interventions
Setanaxib, Placebo
Drug
Lead sponsor
Calliditas Therapeutics Suisse SA
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Los Angeles, California • Pasadena, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 3 Interventional Results available

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

NCT01964430
View directory record Official record
Conditions
Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasms, Pancreatic Diseases, Digestive System Diseases, Endocrine System Diseases, Gemcitabine, Antimetabolites, Antineoplastic
Interventions
nab-Paclitaxel, Gemcitabine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
107
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Nov 3, 2026, 5:24 AM EST
Active, not recruiting Not applicable Interventional Results available

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1

NCT02777528
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic, Aorta, Lesion
Interventions
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
Device · Procedure
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
34
States / cities
Los Angeles, California • Stanford, California • Hartford, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

NCT02724228
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
7 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Oakland, California • Torrance, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional

The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients

NCT00061256
View directory record Official record
Conditions
HIV Infections
Interventions
Alendronate, Calcium carbonate, Vitamin D
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
25 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional Results available

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

NCT00694629
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Recruiting Not applicable Interventional

Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care

NCT06014931
View directory record Official record
Conditions
Post-intensive Care Syndrome
Interventions
Telemedicine ICU Recovery Clinic Visit
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
45 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Exercise Pulmonary Transit Time

NCT04336995
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
contrast echocardiography
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional Results available

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

NCT00604175
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent HPV vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 3, 2026, 5:24 AM EST
Completed Not applicable Interventional Results available

Evaluation of Pain With Belotero® Balance With Integral Lidocaine for Correction of the Nasolabial Folds

NCT03319719
View directory record Official record
Conditions
Correction of Moderate to Severe Nasolabial Folds
Interventions
Belotero® Balance with integral lidocaine, Belotero® Balance
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Nashville, Tennessee • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 3 Interventional Results available

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

NCT02974907
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Pediatric Upper Limb Spasticity

NCT01603602
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 16 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
20
States / cities
Pasadena, California • Pomona, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Nov 3, 2026, 5:24 AM EST
Active, not recruiting Phase 3 Interventional Results available

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353
View directory record Official record
Conditions
Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions
Olaparib 300mg tablets, Placebo to match olaparib 300mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Recruiting Not applicable Interventional

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

NCT04097145
View directory record Official record
Conditions
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Interventions
Edwards PASCAL System, Optimal Medical Therapy
Device · Drug
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
73
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145
View directory record Official record
Conditions
KRAS P.G12C
Interventions
D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Cetuximab
Drug
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Orange, California • Palo Alto, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

NCT03586830
View directory record Official record
Conditions
Obesity and Diabetes Mellitus, Type 2
Interventions
JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Rancho Cucamonga, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Nov 3, 2026, 5:24 AM EST
Completed Phase 1 Interventional

A Study in Adult Subjects With Select Advanced Solid Tumors

NCT02583165
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI1873
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Nov 3, 2026, 5:24 AM EST